French study finds that anticoagulant drugs may help treat lupus erythematosus

Researchers from the University of Bordeaux in France announced on the 1st that platelets play an important role in the development of lupus erythematosus. Anticoagulant drugs may provide a new approach for the treatment of lupus erythematosus.

Lupus erythematosus is an autoimmune disease in which the patient's immune system mistakenly attacks its own cells and tissues, causing inflammation and tissue damage. This disease affects many systems and organs of the body and has complex clinical manifestations. There are currently no effective therapies but the symptoms can be controlled.

The blood of patients with lupus erythematosus is more likely to clot, and the risk of heart disease and stroke is higher. This shows that platelets responsible for clotting may be associated with lupus erythematosus.

The researchers collected platelets from patients with lupus erythematosus. They found that platelets in these patients produced a large amount of proteins that activate a specific type of immune cells to create excess interferon, prompting the body to produce antibodies that attack its own cells. Inflammation.

Researchers used clopidogrel, a human anticoagulant drug that has been used for many years, to treat rats with lupus erythematosus. The results showed that clopidogrel can significantly reduce the inflammation of the rat kidney. In addition, the length of life of the treated mice was approximately 3 months longer than that of untreated mice.

The results of this study were published on the 1st in the United States "Science • Translational Medicine" magazine.

Infrared Forehead Thermometer

Ningbo DOKEE Medical Technology Co., Ltd. ,